The purified vepoloxamer prevents haemolysis in 42-day stored, DEHP/PVC-free red blood cell units

Blood Transfusion

Volumn 15, Issue 2, 2017, Pages 165-171

  Cancelas, Jose A ^a   Rugg, Neeta ^a   Nestheide, Shawnagay ^a   Hill, Sarah E ^a   Emanuele, R Martin ^b   McKenzie, Douglas S ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Mast Therapeutics   (United States)

Author keywords

Blood; Inactivation; Pathogen; Red blood cell; Virus

Indexed keywords

ETHYLENE VINYL ACETATE COPOLYMER; PHOSPHATIDYLSERINE; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; POLYVINYLCHLORIDE; VEPOLOXAMER; MACROGOL DERIVATIVE;

ADULT; AGED; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD DONOR; BLOOD GROUP ABO SYSTEM; CONCENTRATION RESPONSE; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE PRESERVATION; HEMOLYSIS; HUMAN; HUMAN CELL; OSMOTIC FRAGILITY; OXIDATION REDUCTION POTENTIAL; PURIFICATION; ADOLESCENT; BLOOD STORAGE; DRUG EFFECTS; ERYTHROCYTE; FEMALE; ISOLATION AND PURIFICATION; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; SYNTHESIS;

ADOLESCENT; ADULT; AGED; BLOOD PRESERVATION; DIETHYLHEXYL PHTHALATE; ERYTHROCYTES; FEMALE; HEMOLYSIS; HUMANS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYVINYL CHLORIDE;

EID: 85015001820     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2017.0351-16     Document Type: Article

References (42)

1. Heudorf U, Mersch-Sundermann V, Angerer J. Phthalates: toxicology and exposure. Int J Hyg Environ Health 2007; 210: 623-34.
2. Scientific Committee on Emerging and Newly-Identified Health Risks. Preliminary report on the safety of medical devices containing DEHP-plasticized PVC or other plasticizers on neonates and other groups possibly at risk. Health & Consumer Protection, European Commission; 2007. Available at: http://ec.europa.eu/health/ph-risk/committees/04-scenihr/docs/scenihr-o-008.pdf. Accessed on 17/01/2017.
3. Food and Drug Administration, Health CfDaR. Safety assessment of di(2-ethylhexyl)phthalate (DEHP) released from PVC medical devices; 2002. Available at: DeviceRegulationandGuidance/GuidanceDocuments/ UCM080457.pdf. Accessed on 17/01/2017.
4. D'Alessandro A, Nemkov T, Hansen KC. Rapid detection of DEHP in packed red blood cells stored under European and US standard conditions. Blood Transfus 2016; 14:140-4.
5. Jaeger RJ, Rubin RJ. Plasticizers from plastic devices extraction, metabolism, and accumulation by biological systems. Science 1970; 170: 460-2.
6. Jaeger RJ, Rubin RJ. Migration of a phthalate ester plasticizer from polyvinyl chloride blood bags into stored human blood and its localization in human tissues. N Engl J Med 1972; 287: 1114-8.
7. Sasakawa S, Mitomi Y. Di-2-ethylhexylphthalate (DEHP) content of blood or blood components stored in plastic bags. Vox Sang 1978; 34: 81-6.
8. Contreras TJ, Sheibley RH, Valeri CR. Accumulation of DI-2-ethylhexyl phthalate (DEHP) in whole blood, platelet concentrates, and platelet-poor plasma. Transfusion 1974; 14: 34-46.
9. Inoue K, Kawaguchi M, Yamanaka R, et al. Evaluation and analysis of exposure levels of di(2-ethylhexyl) phthalate from blood bags. Clin Chim Acta 2005; 358: 159-66.
10. Jaeger RJ, Rubin RJ. Plasticisers from P.V.C. Lancet 1970; 2: 778.
11. AuBuchon JP, Estep TN, Davey RJ. The effect of the plasticizer di-2-ethylhexyl phthalate on the survival of stored RBCs. Blood 1988; 71: 448-52.
12. Estep TN, Pedersen RA, Miller TJ, et al. Characterization of erythrocyte quality during the refrigerated storage of whole blood containing di-(2-ethylhexyl) phthalate. Blood 1984; 64: 1270-6.
13. Rock G, Tocchi M, Ganz PR, et al. Incorporation of plasticizer into red cells during storage. Transfusion 1984; 24: 493-8.
14. Kora S, Sado M, Koike H, et al. Protective effect of the plasticizer di(2-ethylhexyl) phthalate against damage of the mitochondrial membrane induced by calcium: possible participation of the adenine nucleotide translocator. Biochim Biophys Acta 1989; 985: 286-92.
15. Agency for Toxic Substances and Disease Registry. Public Health Service, US Department of Health and Human Services. Toxicological profile for di(2-ethylhexyl)phthalate; 2002. Available at: https://www.atsdr.cdc.gov/toxprofiles/tp9.pdf. Accessed on 17/01/2017.
16. Hurst CH, Waxman DJ. Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol Sci 2003; 74: 297-308.
17. Takeshita A, Inagaki K, Igarashi-Migitaka J, et al. The endocrine disrupting chemical, diethylhexyl phthalate, activates MDR1 gene expression in human colon cancer LS174T cells. J Endocrinol 2006; 190: 897-902.
18. Rael LT, Bar-Or R, Ambruso DR, et al. Phthalate esters used as plasticizers in packed red blood cell storage bags may lead to progressive toxin exposure and the release of pro-inflammatory cytokines. Oxid Med Cell Longev 2009; 2: 166-71.
19. Colbassani HJ, Barrow DL, Sweeney KM, et al. Modification of acute focal ischemia in rabbits by poloxamer 188. Stroke 1989; 20: 1241-6.
20. Hunter RL, Papadea C, Gallagher CJ, et al. Increased whole blood viscosity during coronary artery bypass surgery. Studies to evaluate the effects of soluble fibrin and poloxamer 188. Thromb Haemost 1990; 63: 6-12.
21. Justicz AG, Farnsworth WV, Soberman MS, et al. Reduction of myocardial infarct size by poloxamer 188 and mannitol in a canine model. Am Heart J 1991; 122: 671-80.
22. Mayer DC, Strada SJ, Hoff C, et al. Effects of poloxamer 188 in a rabbit model of hemorrhagic shock. Ann Clin Lab Sci 1994; 24: 302-11.
23. Hunter RL, Jagannath C, Tinkley A, et al. Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331. Antimicrob Agents Chemother 1995; 39: 435-9.
24. Jagannath C, Allaudeen HS, Hunter RL. Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob Agents Chemother 1995; 39: 1349-54.
25. Jagannath C, Emanuele MR, Hunter RL. Activities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in mice. Antimicrob Agents Chemother 1999; 43: 2898-903.
26. Jagannath C, Emanuele MR, Hunter RL. Activity of poloxamer CRL-1072 against drug-sensitive and resistant strains of Mycobacterium tuberculosis in macrophages and in mice. Int J Antimicrob Agents 2000; 15: 55-63.
27. Jagannath C, Sepulveda E, Actor JK, et al. Effect of poloxamer CRL-1072 on drug uptake and nitric-oxidemediated killing of Mycobacterium avium by macrophages. Immunopharmacology 2000; 48: 185-97.
28. Moghimi SM, Hunter AC, Dadswell CM, et al. Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim Biophys Acta 2004; 1689: 103-13.
29. Harting MT, Jimenez F, Kozar RA, et al. Effects of poloxamer 188 on human PMN cells. Surgery 2008; 144: 198-203.
30. Zhang R, Hunter RL, Gonzalez EA, et al. Poloxamer 188 prolongs survival of hypotensive resuscitation and decreases vital tissue injury after full resuscitation. Shock 2009; 32: 442-50.
31. Hunter RL, Luo AZ, Zhang R, et al. Poloxamer 188 inhibition of ischemia/reperfusion injury: evidence for a novel antiadhesive mechanism. Ann Clin Lab Sci 2010; 40: 115-25.
32. Toth K, Wenby RB, Meiselman HJ. Inhibition of polymerinduced red blood cell aggregation by poloxamer 188. Biorheology 2000; 37: 301-12.
33. Sandor B, Marin M, Lapoumeroulie C, et al. Effects of Poloxamer 188 on red blood cell membrane properties in sickle cell anaemia. Br J Haematol 2016; 173: 145-9.
34. Armstrong JK, Meiselman HJ, Fisher TC. Inhibition of red blood cell-induced platelet aggregation in whole blood by a nonionic surfactant, poloxamer 188 (RheothRx injection). Thromb Res 1995; 79: 437-50.
35. AuBuchon JP, Cancelas JA, Herschel L, et al. In vitro and in vivo evaluation of LEUKOSEP HRC-600-C leukoreduction filtration system for red cells. Transfusion 2006; 46: 1311-5.
36. Bandarenko N, Cancelas J, Snyder EL, et al. Successful in vivo recovery and extended storage of additive solution (AS)-5 red blood cells after deglycerolization and resuspension in AS-3 for 15 days with an automated closed system. Transfusion 2007; 47: 680-6.
37. Cancelas JA, Rugg N, Fletcher D, et al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011; 51: 1460-8.
38. van der Meer PF, Cancelas JA, Vassallo RR, et al. Evaluation of the overnight hold of whole blood at room temperature, before component processing: platelets (PLTs) from PLT-rich plasma. Transfusion 2011; 51: 45S-49S.
39. Kalfa TA, Pushkaran S, Mohandas N, et al. Rac GTPases regulate the morphology and deformability of the erythrocyte cytoskeleton. Blood 2006; 108: 3637-45.
40. Pei S, Minhajuddin M, Callahan KP, et al. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem 2013; 288: 33542-58.
41. O'Neill JS, Reddy AB. Circadian clocks in human red blood cells. Nature 2011; 469: 498-503.
42. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nature Methods 2012; 9: 671-5.